Creatinine-weight ratio to detect fatty liver in metabolic syndrome
Part of Hormones & metabolism clinical trials.
This study looks at whether a simple blood test combined with your weight can help find fatty liver disease in people with metabolic syndrome. It may offer an easier way to check liver health without more invasive tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have metabolic syndrome, which means having at least three of these: large waist, high triglycerides, low HDL (good) cholesterol, high blood pressure, or high blood sugar.
- You must not have other liver diseases, such as hepatitis B or C.
- You must not have significant alcohol intake or take drugs that can harm the liver.
- You must not have advanced kidney disease, cancer, be pregnant, or have an active infection or inflammatory condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study looks at a new way to check how well your body handles sugar (glucose disposal rate) to detect fatty liver linked to metabolic syndrome. It may help doctors diagnose this condition more easily.
This study tests a new, non-invasive way to diagnose a type of fatty liver disease (MASLD) in children with obesity. It aims to find simple blood or imaging markers that can detect the condition without a liver biopsy.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study classifies fatty liver disease (MAFLD) by examining liver tissue samples. It aims to better understand how metabolic risk factors like high blood sugar, high blood pressure, or excess weight relate to the liver's condition.
Hear when a new Metabolic Syndrome (MetS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.